We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-6.32%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$742M
AUM Growth
-$262M
Cap. Flow
-$189M
Cap. Flow %
-25.45%
Top 10 Hldgs %
99.97%
Holding
11
New
–
Increased
2
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$14.2M
2
AMRN
Amarin Corp
AMRN
+$6M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$205M
2
MRSN
Mersana Therapeutics
MRSN
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.22B
$197M 26.57%
7,042,200
-6,997,800
-50% -$205M
BIIB icon
2
Biogen
BIIB
$30B
$165M 22.26%
643,000
– –
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$158M 21.26%
16,390,000
– –
INVA icon
4
Innoviva
INVA
$1.55B
$94.5M 12.73%
7,277,000
– –
GILD icon
5
Gilead Sciences
GILD
$162B
$69M 9.29%
920,400
– –
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.8B
$41.2M 5.55%
366,000
+134,700
+58% +$14.2M
AMRN
7
Amarin Corp
AMRN
$299M
$9.61M 1.29%
522,123
+276,623
+113% +$6M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.28B
$5.49M 0.74%
775,000
– –
VOR icon
9
Vor Biopharma
VOR
$1.15B
$1.31M 0.18%
30,900
– –
MRSN
10
DELISTED
Mersana Therapeutics
MRSN
$699K 0.09%
22,000
-83,316
-79% -$3.96M
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$254K 0.03%
185,183
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Sarissa Capital Management held 11 positions worth $742M, down 26% from $1B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management withdrew a net $189M in Q3 2023, reducing 2 holdings. Its largest reduction was Alkermes, cutting an estimated $205M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Sarissa Capital Management added an estimated $14.2M to Neurocrine Biosciences.

  • Sarissa Capital Management added most to Neurocrine Biosciences in Q3 2023, an estimated $14.2M increase.
  • Sarissa Capital Management's biggest Q3 2023 reduction was Alkermes, cutting an estimated $205M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $742M portfolio in Q3 2023.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q3 2023.
  • Sarissa Capital Management's portfolio value fell 26% quarter-over-quarter to $742M.

Based on Sarissa Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.